Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

ABSTRACT:

Background

The consequences of low prostate-specific antigen (PSA) in high-grade (Gleason 8-10) prostate cancer are unknown.

Objective

To evaluate the clinical implications and genomic features of low-PSA, high-grade disease.

Design, setting, and participants

This was a retrospective study of clinical data for 494 793 patients from the National Cancer Data Base and 136 113 patients from the Surveillance, Epidemiology, and End Results program with cT1-4N0M0 prostate cancer (median follow-up 48.9 and 25.0 mo, respectively), and genomic data for 4960 patients from the Decipher Genomic Resource Information Database. Data were collected for 2004-2017.

Outcome measurements and statistical analysis

Multivariable Fine-Gray and Cox regressions were used to analyze prost

SUBMITTER: Mahal BA 

PROVIDER: S-EPMC6615042 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature